# A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)

> **NCT03393975** · PHASE3 · COMPLETED · sponsor: **Baxalta now part of Shire** · enrollment: 52 (actual)

## Conditions studied

- Thrombotic Thrombocytopenic Purpura (TTP)

## Interventions

- **BIOLOGICAL:** TAK-755
- **BIOLOGICAL:** Standard of care

## Key facts

- **NCT ID:** NCT03393975
- **Lead sponsor:** Baxalta now part of Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-13
- **Primary completion:** 2023-12-28
- **Final completion:** 2024-05-30
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2026-02-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03393975

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03393975, "A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT03393975. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*